Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999, focusing on the R&D, production, and sales of wet wipes [2] - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2] - In Q1 2025, the company reported a revenue of 124 million CNY and a net profit of 10.06 million CNY [2] Business Operations - The company's own brand revenue currently accounts for a low percentage, with a primary focus on OEM (Original Equipment Manufacturer) business [3] - Gross margin for international clients is higher than that for domestic clients [3] - The procurement price trend for non-woven fabric has been stable in recent years [3] Product Development - The core R&D for cosmetic formulations is handled by the Shanghai R&D center, leveraging the advantages of the Yangtze River Delta biotechnology industry [3] - Revenue from pet wipes is currently low [3] Cost Management - The U.S. factory aims to control costs by introducing automated production lines and optimizing management processes to enhance operational efficiency and cost structure [3] Capacity Utilization - The company's capacity utilization rate is approximately 80% [3] Subsidiary Operations - The subsidiary, Jiechuan Medical, is currently in a strategic adjustment phase, with cautious investment based on overall business layout and resource optimization [3] Compliance - The investor relations activity adhered strictly to the Shenzhen Stock Exchange's regulations, with no significant undisclosed information leaks reported [3]
洁雅股份(301108) - 2025年6月17日 投资者关系活动记录表